CYP2D6 gene deletion allele in patients with neuroleptic malignant syndrome: Preliminary report

Psychiatry and Clinical Neurosciences

Volumn 59, Issue 4, 2005, Pages 504-507

  Kato, Daiji ^a   Kawanishi, Chiaki ^a   Kishida, Ikuko ^a   Furuno, Taku ^a   Matsumura, Takehiko ^a   Hasegawa, Hana ^a   Suzuki, Kyoko ^a   Hirayasu, Yoshio ^a  

^a YOKOHAMA CITY UNIVERSITY   (Japan)

Author keywords

CYP2D6; Gene deletion; Genetic polymorphism; Neuroleptic malignant syndrome; Poor metabolizer

Indexed keywords

CHLORPROMAZINE; CREATINE KINASE; DIAZEPAM; HALOPERIDOL; LEVOMEPROMAZINE; NEUROLEPTIC AGENT; PEROSPIRONE; PROPERICYAZINE; UNCLASSIFIED DRUG;

ADULT; ALLELE; ARTICLE; CASE REPORT; CYP2D6 GENE; DELIRIUM; DIAPHORESIS; DNA POLYMORPHISM; DROWSINESS; DRUG ACCUMULATION; DYSARTHRIA; DYSPHAGIA; FEMALE; FEVER; GENE DELETION; GENETIC ASSOCIATION; GENOTYPE; HUMAN; HYPERSALIVATION; LEUKOCYTE; MALE; NEUROLEPTIC MALIGNANT SYNDROME; OLIGURIA; POLYMERASE CHAIN REACTION; RESTRICTION FRAGMENT LENGTH POLYMORPHISM; RIGIDITY; SCHIZOPHRENIA; SIDE EFFECT; TACHYCARDIA;

ADULT; ALLELES; ANTIPSYCHOTIC AGENTS; CYTOCHROME P-450 CYP2D6; DNA; FEMALE; GENE DELETION; HUMANS; MALE; MIDDLE AGED; NEUROLEPTIC MALIGNANT SYNDROME; POLYMORPHISM, RESTRICTION FRAGMENT LENGTH; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; SCHIZOPHRENIA;

EID: 23744493563     PISSN: 13231316     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1440-1819.2005.01405.x     Document Type: Article

References (16)

1. Bertilsson L, Dahl ML, Dalen P, Al-Shurbaji A. Molecular genetics of CYP2D6: clinical relevance with focus on psychotropic drugs. Br. J. Clin. Pharmacol. 2002; 53: 111-122
2. Kawanishi C, Furuno T, Onishi H et al. Lack of association in Japanese patients between neuroleptic malignant syndrome and a debrisoquine 4-hydroxylase genotype with low enzyme activity. Psychiatr. Genet. 2000; 10: 145-147.
3. Pope HG, Keck PE, McElroy SL. Frequency and presentation of neuroleptic malignant syndrome in a large psychiatric hospital. Am. J. Psychiatry 1983; 143: 1227-1233.
4. Kawanishi C. Genetic predisposition to neuroleptic malignant syndrome: implications for antipsychotic therapy. Am. J. Pharmacogenomics 2003; 3: 89-95.
5. Kawanishi C, Lundgren S, Ågren H, Bertilsson L. Increased incidence of CYP2D6 gene duplication in patients with persistent mood disorders: ultrarapid metabolism of antidepressants as a cause of nonresponse. A pilot study. Eur. J. Clin. Pharmacol. 2004; 59: 803-807.
6. Smith CA, Gough AC, Leigh PN et al. Debrisoquine hydroxylase gene polymorphism and susceptibility to Parkinson's disease. Lancet 1992; 339: 1375-1377.
7. Scordo MG, Spina E. Cytochrome P450 polymorphisms and response to antipsychotic therapy. Pharmacogenomics 2002; 3: 201-218.
8. Scordo MG, Spina E, Romeo P et al. CYP2D6 genotype and antipsychotic-induced extrapyramidal side effects in schizophrenic patients. Eur. J. Clin. Pharmacol. 2000; 56: 679-683.
9. Ellingrod VL, Schultz SK, Arndt S. Association between cytochrome P450 2D6 (CYP2D6) genotype, antipsychotic exposure, and abnormal involuntary movement scale (AIMS) score. Psychiatr. Genet. 2000; 10: 9-11.
10. Kapitany T, Meszaros K, Lenzinger E et al. Genetic polymorphisms for drug metabolism (CYP2D6) and tardive dyskinesia in schizophrenia. Schizophr. Res. 1998; 32: 101-106.
11. Ohmori O, Suzuki T, Kojima H et al. Tardive dyskinesia and debrisoquine 4-hydroxylase (CYP2D6) genotype in Japanese schizophrenics. Schizophr. Res. 1998; 32: 107-113.
12. Adityanjee, Aderibigbe YA, Mathews T. Epidemiology of neuroleptic malignant syndrome. Clin. Neuropharmacol. 1999; 22: 151-158.
13. Iwahashi K. CYP2D6 genotype and possible susceptibility to the neuroleptic malignant syndrome. Biol. Psychiatry 1994; 36: 780-782.
14. Kawanishi C, Shimoda Y, Fujimaki J et al. Mutation involving cytochrome P450 II D6 in two Japanese patients with neuroleptic malignant syndrome. J. Neurol. Sci. 1998; 160: 102-104.
15. Someya T, Shimoda K, Suzuki Y et al. Effect of CYP2D6 genotypes on the metabolism of haloperidol in a Japanese psychiatric population. Neuropsychopharmacology 2003; 28: 1501-1505.
16. Kishida I, Kawanishi C, Furuno T et al. Association in Japanese patients between neuroleptic malignant syndrome and functional polymorphisms of the dopamine D(2) receptor gene. Mol. Psychiatry 2004; 9: 293-298.